RxDoctor Payments Data

Nathan Fitzgerald, PA

Medical · Wasilla, AKNPI 1043738461

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $661 of the $761 with a category attached, or 86.9%. 12 manufacturers reported payments, led by Sumitomo Pharma America, Inc. at 27.3% of the total. 2025 is the largest year on record at $282, more than ten times the $20 reported in 2021.

$761in general payments, 2019–2025

Across 24 payments — averaging $31.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$208
  • AbbVie$160
  • Astellas Pharma US Inc$100
  • C. R. Bard, Inc. & Subsidiaries$82
  • 180 Medical, Inc.$53
  • Boston Scientific$29
  • plus $128 from 6 others

What the payments were for

  • Food & beverage$66187%
  • Education$10013%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sumitomo Pharma America, Inc.6$208
AbbVie6$160
Astellas Pharma US Inc1$100
C. R. Bard, Inc. & Subsidiaries2$82
180 Medical, Inc.2$53
Boston Scientific1$29
Johnson & Johnson1$25
Urogen Pharma, Inc.1$23
Olympus America Inc.1$22
Pfizer1$21
Rochester Medical Corporation1$19
Novartis1$18

How this compares

$761 in reported general payments places this provider in the 60th percentile of 140 medical providers in Alaska.

See all medical providers in Alaska

Medicare billing

Part B allowed, 2024
$210,793
Medicare patients
667
Services billed
5,884

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron87$95,105
GemtesaVibegron12$16,144
Tamsulosin Hcl408$13,011
Solifenacin Succinate56$8,584
Tolterodine Tartrate ErTolterodine Tartrate12$4,057
Dutasteride45$2,528
Tadalafil35$1,989
Silodosin12$1,520
NitrofurantoinNitrofurantoin Macrocrystal23$1,156
Testosterone Cypionate20$1,077
Finasteride28$650
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst23$288
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav23$207
Ciprofloxacin Hcl45$148
Levofloxacin16$93

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$100$95,10587 claims
Sumitomo Pharma America, Inc.Gemtesa$208$16,14412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 140 medical providers in Alaska.

Other medical in Wasilla

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →